Considering the unsatisfactory results of salvage therapies for patients with relapsed/refractory acute myeloid leukaemia (R/R-AML), their value before allogeneic haematopoietic stem cell transplantation (HSCT) remains questionable. However, direct allogeneic HSCT following established conditioning regimens applied in patients with R/R-AML during active disease has been equally disappointing. In this retrospective observational study, highdose melphalan, as part of a sequential preparative regimen, followed by a total body irradiation (4 9 2 Gy)-based or a treosulfan-based dose-adapted conditioning therapy for allogeneic HSCT was administered to 292 adult patients (median age 56 years, range 17-74) with primary refractory (144 patients), secondary refractory (97 patients) or relapsed AML (51 patients).
Summary
Considering the unsatisfactory results of salvage therapies for patients with relapsed/refractory acute myeloid leukaemia (R/R-AML), their value before allogeneic haematopoietic stem cell transplantation (HSCT) remains questionable. However, direct allogeneic HSCT following established conditioning regimens applied in patients with R/R-AML during active disease has been equally disappointing. In this retrospective observational study, highdose melphalan, as part of a sequential preparative regimen, followed by a total body irradiation (4 9 2 Gy)-based or a treosulfan-based dose-adapted conditioning therapy for allogeneic HSCT was administered to 292 adult patients (median age 56 years, range 17-74) with primary refractory (144 patients), secondary refractory (97 patients) or relapsed AML (51 patients).
Overall survival rates at 3 years were 34%, 29% and 41%, respectively. Risk factors associated with an inferior survival were higher age, transplantation from a human leucocyte antigen-mismatched donor and high disease burden. Patients transplanted with blast infiltration <20% showed a notable survival rate of 51% at 3 years. In particular, patients with primary refractory AML showed a more favourable outcome when transplanted early during their disease course. Thus, high-dose melphalan-based sequential conditioning chemotherapy followed by an allogeneic HSCT is feasible and enables long-term remission to be achieved in a substantial proportion of patients with active R/R-AML.
Keywords: acute myeloid leukaemia, conditioning, haematological malignancies, stem cell transplantation, residual disease.
Substantial advances in acute myeloid leukaemia (AML) research have hugely enriched our understanding of the molecular mechanisms underlying the evolution of this disease. However, to date, the majority of AML patients still show insufficient response to induction therapy or relapse after initial complete remission (CR). For these patients, allogeneic haematopoietic stem cell transplantation (HSCT) remains a valid option to achieve cure; without HSCT long-term overall survival rates scarcely reach 5% Schlenk et al, 2010; Roboz et al, 2014) . In the past, various salvage chemotherapy regimens aiming to induce CR prior to allogeneic HSCT have been used for patients with relapsed/refractory AML (R/R-AML). Most of these regimens are associated with substantial toxicities that, in a substantial subset of the patients, even hamper subsequent curative allogeneic HSCT. Moreover, complete response rates to common salvage regimens rarely exceed 50% in patients with late AML relapse and decrease to 10-15% in patients with refractory AML or early relapse (Thol et al, 2015; Wattad et al, 2017) . The application of further salvage regimens is unlikely to significantly improve remission status for those patients with response failure. Thus, in face of the unsatisfactory results of salvage chemotherapy regimens, this strategy has recently been discussed controversially. Previous studies have shown that allogeneic HSCT can still achieve long-term survival, and even cure, for AML patients transplanted during the active disease stage (Biggs et al, 1992; Michallet et al, 2000; Fung et al, 2003; Sayer et al, 2003; Schmid et al, 2005 Schmid et al, , 2006 Duval et al, 2010) . However, long-term survival rates of AML patients post allogeneic HSCT are significantly higher for patients transplanted in CR when compared to those transplanted with active leukaemia (Sierra et al, 1997; Blum et al, 2006; Schlenk et al, 2010) . Thus, for patients with active R/R-AML who are eligible for allogeneic HSCT, haematologists have to consider delivering either a maximal reduction of blast count prior to transplantation or minimal toxicity before conditioning therapy.
Common conditioning regimens followed by allogeneic HSCT of patients with active AML have shown disappointing results (Stelljes et al, 2005; Ringden et al, 2009; Luger et al, 2012) . Therefore, the concept of sequential therapy as preparative regimens for allogeneic HSCT was developed (Schmid et al, 2005; Sauer et al, 2015) , and recently, two clinical trials using this strategy have shown encouraging results in respect of both, treatment-related toxicity and antileukaemic efficacy (Schmid et al, 2005 (Schmid et al, , 2006 . Furthermore, melphalan-based conditioning regimens prior to both, autologous and allogeneic HSCT have shown promising results in terms of relapse incidences in AML patients as well as acceptable toxicity profiles, particularly favourable nonhaematological toxicities (Bug et al, 2005; Shimoni et al, 2007; Baron et al, 2014; Ringden et al, 2016; Gorin et al, 2017) . Thus, we hypothesized that a sequential treatment approach, implementing high-dose melphalan followed by established total body irradiation (TBI)-based or chemotherapy-based dose-adapted conditioning, may exert particular profound antileukaemic efficacy without substantially increasing toxicity in patients with active R/R-AML.
Patients and methods

Patients and treatment
From April 2005 to May 2016, 292 patients with R/R-AML received an allogeneic HSCT at the Bone Marrow Transplantation Centres of the University Hospitals of Muenster and Essen. Numbers of de novo AML, secondary AML and therapy-related AML were 211, 54 and 27, respectively. During the observational period, all patients with R/R-AML who were fit for intensive conditioning were included in our analysis. Patients with R/R-AML but unfit for intensive conditioning received alternative conditioning regimens and were excluded from this study. An institutional review board approved this retrospective evaluation; written informed consent was obtained from all patients. Results were analysed as of 10 April 2017.
All patients were conditioned with a single infusion of melphalan at a total dose of 140 mg/m 2 (with the exception of 19 patients, who received dosages of 100, 150 or 200 mg/ m 2 ), followed by fludarabine at a total dose of 120 mg/m 2 on four consecutive days and 8 Gy TBI applied in four fractions of 2 Gy on two consecutive days (Mel/8GyTBI/Flu) or followed by fludarabine at a total dose of 150 mg/m 2 on five consecutive days and treosulfan at a total dose of 42Á000 mg/ m 2 on three consecutive days (Mel/Treo/Flu). The decision to administer the TBI or treosulfan-based regimen was based on the respective centre policy which was changed in one centre during observation period. In addition, elderly patients (>60 years) and/or with contraindication for TBI received treosulfan-based regimen. Median time between melphalan and continuation of therapy was 5 days (range 1-18 days), resulting in an overall duration of conditioning prior to HSCT of 11 days in most patients. Additional pretreatment with antithymocyte globulin (ATG) was applied in 157 of the 222 patients with an unrelated donor and in 44 of the 70 patients with a human leucocyte antigen (HLA)-identical sibling donor, according to each individual centre policy. One centre used ATG for all patients receiving transplants from related and unrelated donors. In the second centre, ATG was added to the conditioning regimen after October 2013 for unrelated transplants. ATG Fresenius at a dose of 30-40 mg/kg body weight (bw) was used throughout the observation period (because ATG usage was dependent on centre policy and changed during the observational period we did not include ATG application in our uni-and multivariate analyses). With the exception of two patients (both received tacrolimus and mycophenolate mofetil), all patients received ciclosporin for acute graft-versus-host disease (GvHD) prophylaxis in combination with methotrexate (89 patients), mycophenolate mofetil (197 patients) or both (4 patients). None of the patients included in our study received maintenance therapy.
Treatment of relapse consisted of rapid tapering of immunosuppressive prophylaxes followed by donor lymphocyte infusions whenever feasible. Additional treatments consisted of hypomethylating agents, sorafenib, conventional chemotherapies or second allogeneic transplantation.
Donor selection and blood stem cell harvest
Unrelated donors were selected based on the compatibility for HLA-A, -B, -C, DRB1 and DQB1 by high-resolution DNA typing. Related donors were HLA-typed at least for HLA-A, -B, -C and DRB1. 281 patients received peripheral blood stem cells (PBSC), 10 patients received a bone marrow graft and one patient received both. Mobilization of PBSCs with granulocyte colony-stimulating factor and aphereses were performed according to the policy of the collection centre. PBSC grafts contained a median of 7Á3 9 10 6 /kg bw (range, 1Á61 9 10 6 to 26Á6 9 10 6 ) CD34 + stem cells. Stem cell grafts were infused on day 0 without further 
Definitions
Disease status by peripheral blood and bone marrow aspiration was assessed before allogeneic HSCT and defined according to standard morphological criteria (Cheson et al, 2003) and clinical course as follows: refractory AML was defined as bone marrow blasts >5% and/or extramedullary AML manifestation and/or repeated detection of leukaemic blasts in the peripheral blood, after one or two courses of intensive induction treatment (primary refractory AML) or, in case of relapsed AML, after at least one course of intensive salvage therapy (secondary refractory AML). Patients with untreated relapse achieved a CR after conventional first line induction treatment and were transplanted with relapsed AML without intensive salvage treatment. CR after allogeneic HSCT was defined as leukaemia-free state (no bone marrow and no extramedullary disease manifestations) and engraftment of donor cells (documented by at least one chimerism from blood and/or bone marrow and absolute neutrophil count [ANC] >0Á5 9 10 9 /l). At least one chimerism analysis with documented complete donor cell chimerism (≥95%) was required for the definition of donor cell engraftment together with an ANC > 0Á5 9 10 9 /l after allogeneic HSCT.
Chimerism was asessed according to centre policy with analysis of blood and/or whole bone marrow cells and, in some patients, with additional subpopulation chimerisms (e.g. CD34 positive bone marrow cells). Non-relapse mortality (NRM) was defined as death without disease relapse or refractoriness and, when used in connection with a percentage estimation, was described as deaths observed/patient population of interest.
Risk classification of AML patients by cytogenetic and/or molecular genetic findings was done according to the European Leukaemia Net (ELN) recommendations .
Four different risk scores for allogeneic HSCT were calculated: the haematopoietic cell transplantation comorbidity index (HCT-CI), the European Group for Blood and Marrow Transplantation (EBMT) risk score, the refined disease-riskindex (DRI) from the Center for International Blood and Marrow Transplant Research and the Pre-transplant Assessment of Mortality Score (PAM score) (Sorror et al, 2005; Armand et al, 2012 Armand et al, , 2014 Au et al, 2015; Shouval et al, 2015) .
Statistical analysis
Overall survival (OS) was survival calculated from the day of allogeneic HSCT until death from any cause, with censoring of patients known to be alive at the time of last follow-up. Relapse-free survival (RFS) was calculated from the day of transplantation to relapse or death. Both OS and RFS were analysed by Kaplan-Meier survival estimations. Probabilities of NRM and relapse were calculated using cumulative incidence estimates to accommodate competing risks. The Gray test was used to compare cumulative incidence of relapse and non-relapse mortality as competing risks.
Hazard ratios with 95% confidence intervals (95% CI) for OS and RFS were estimated by Cox regression analysis. For determination of risk factors, a multivariate Cox regression analysis was performed including the identified risk factors (P < 0Á2 in univariate log-rank test) with backward selection.
A P < 0Á05 was considered to indicate statistically significant differences in all analyses.
All statistical analyses were performed by IBM SPSS STATIS-TICS FOR WINDOWS, version 24.0 (IBM Corp., Armonk, NY, USA) and XLSTAT version 19.01 (Addinsoft, Paris, France).
Results
Patient characteristics
A total number of 292 patients with active AML (49% with primary refractory AML, 33% with secondary refractory AML and 18% with untreated AML relapse) were included in our analysis. Median age of all patients at transplantation was 56 years (range 17-74 years), with 39 patients aged <40 years (13%), 140 patients aged 40-59 (48%) and 113 patients (39%) older than 60 years. Detailed patients' characteristics are depicted in Table I . All patients received at least one cytarabine-based standard induction therapy. Patients with primary refractory AML were defined as having >5% bone marrow blasts after 1-2 cycles of intensive chemotherapy. Elderly patients (>60 years) and/or patients with adverse cytogenetic risk profile received only one cycle of induction chemotherapy (n = 28). In general, patients included in our study received 1-7 cycles of intensive chemotherapy prior to HSCT. One patient received 28 cycles of 5-azacytidine prior to HSCT. Patients with secondary refractory AML had a more intense treatment history than primary refractory patients, with a median number of six therapies (range 2-14). The median time from initial diagnosis to transplant was 4 months for patients with primary refractory AML, 13 months for patients with secondary refractory AML and 11 months for patients with untreated relapse.
Outcome
Median follow-up after allogeneic HSCT of all patients alive at last follow-up was 4Á8 years. Of the 292 patients in our study, 272 patients were available for engraftment analysis and all of these patients showed ANC engraftment. 20 patients died before engraftment due to severe infectious complications. Neutrophil engraftment was documented at a median of 17 days after transplant (range 8-50). Platelet engraftment, defined as platelet count >20 9 10 9 /l without Fig 1A) , respectively. Projected RFS at 1 and 3 years after transplant was 41% (95% CI, 35-46%) and 31% (95% CI, 26 37%, Fig 1B) , respectively. Cumulative incidences of NRM and relapse were 22% (95% CI, 18-28%, Fig 1D) and 12% (95% CI, 9-17%, Fig 1C) at day 100 after transplant, and 36% (95% CI, 31-42%) and 34% (95% CI, 28-41%) at 1 year after transplant, respectively. The 3-year OS of patients transplanted with primary refractory AML or secondary refractory AML showed no significant difference with 34% (95% CI, 26-42%) and 29% (95% CI, 20-28%), respectively ( Fig 2C, Table II ). Patients transplanted with an untreated relapsed disease showed a trend for improved survival compared to both other patient groups (41%, 95% CI, 27-56%, P = 0Á165). Factors associated with an inferior OS were older age and, most importantly, higher leukaemic burden (indicated by leukaemic blast infiltration ≥20% in the bone marrow and/or leukaemic blasts in the peripheral blood ≥20%, P < 0Á001), a time interval of 5-9 months between first diagnosis and allogeneic HSCT, and transplantation from an HLA-mismatched unrelated donor (Table II) . In particular, patients transplanted from HLA-mismatched unrelated donor had a significantly higher risk for NRM of 55% (95% CI, 27-56%) at 1 year, compared to those transplanted from a HLA-matched related (34%, 95% CI, 24-48%) or unrelated donor (28%, 95% CI, 22-37%). In addition, adverse risk factors for NRM were older age, pre-existing infection prior to start of conditioning therapy and a higher comorbidity index (HCT-CI > 3). patients whose data were censored at the last time they were known to be alive or (B, C) whose data were censored at the last time they were known to be alive and in complete remission. Multivariate analysis of risk factors revealed that high disease burden prior to conditioning (P < 0Á001), longer time interval between first diagnosis and transplantation (P = 0Á039) with the exception of patients with late (>9 months after initial diagnosis) relapse, and transplantation from an HLA-mismatched unrelated donor (P = 0Á049) were independently associated with inferior OS. High risk disease according to cytogenetic and molecular genetic aberrations as an adverse risk factor showed a trend in this analysis (P = 0Á052).
Graft-versus-host disease
Acute GvHD grade 1-4 occurred in 29 patients (41%) transplanted from an HLA-identical sibling donor, 95 patients (61%) transplanted from a HLA-matched unrelated donor and 39 patients (60%) transplanted from a HLA-mismatched unrelated donor. Acute GvHD grade 3-4 was observed in 8 (11%), 20 (13%) and 14 (21%) patients, respectively. Of the 134 patients with acute GvHD transplanted from an unrelated donor, 43 patients (32%) relapsed with their AML, compared to 12 out of 29 patients (41%) with acute GvHD transplanted from an HLA-identical sibling donor. Twentyseven of the 218 patients still alive after day 100 developed a limited chronic GvHD (12%) and 48 patients developed extensive chronic GvHD (22%). Twenty-three of the 27 patients with limited chronic GvHD and 40 of the 48 patients with extensive GvHD were transplanted from unrelated donors. Acute and chronic GvHD did not show statistically significant impact on OS.
Subgroups
Subgroup analyses revealed that patients with primary refractory AML had a more favourable outcome with respect to OS when the allogeneic HSCT was performed early, within 2-4 months after initial diagnosis (Table III) . Higher disease burden was significantly associated with a worse OS, particularly in patients with primary or secondary refractory AML. Most likely due to the smaller patient number in the various subgroups analysed in Table II , transplantation from a mismatched unrelated donor (MUD) was only significantly associated with a worse survival in patients with primary refractory disease. In addition, pre-existing prolonged neutropenia and/or infection at start of conditioning and/or with relevant co-morbidities (HCT-CI > 3) also impacted survival outcome in this subgroup. Interestingly, even patients with adverse risk features, such as higher age, high risk cytogenetics or relevant comorbidities, showed survival rates of 12-40% at 3 years.
Discussion
Currently, most patients with R/R-AML are transferred to further salvage chemotherapies with the intent to improve remission status prior to allogeneic HSCT or to alternative therapies, the latter usually as experimental or palliative approach. However, response rates of these patients to salvage chemotherapies are rather disappointing and the toxicity profiles are frequently unfavourable (Thol et al, 2015; Dohner et al, 2017; Wattad et al, 2017) . Moreover, whereas novel targeted therapies have been shown to improve patient outcome for subsets of AML patients when combined with conventional induction therapy (Stone et al, 2017) , none of the new substances is able to substantially prolong the survival of patients with R/R-AML, and are much less likely to achieve cure (Gao & Estey, 2015) . In contrast, allogeneic transplantation has shown the potential to deliver long-term survival in a significant proportion of these patients (Duval et al, 2010; Craddock et al, 2011) . However, allogeneic HSCT following established conditioning regimens has been largely disappointing in AML patients when applied during the active disease stage (Stelljes et al, 2005; Ringden et al, 2009; Schlenk et al, 2010; Luger et al, 2012; Pfrepper et al, 2016; Todisco et al, 2017) . Here, we present data on 292 patients with active R/R-AML treated with two different melphalan- 95% CI, 95% confidence interval; AML, acute myeloid leukaemia; BM, bone marrow; CMV, cytomegalovirus; DRI, disease risk index; ELN, European Leukaemia Net; HCT-CI, Haematopoietic Cell Transplantation-Comorbidity Index; HLA, human leucocyte antigen; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; NRM, non-relapse mortality; OS, overall survival; PB, peripheral blood; TBI, total body irradiation. *Twenty-five patients with no available blast counts or with extramedullary AML without bone marrow involvement were excluded from this subgroup analysis. †Not known for two patients. ‡Forty-six patients with incomplete cytogenetic/molecular data were classified as intermediate II. 95% CI, 95% confidence interval; BM, bone marrow; CMV, cytomegalovirus; DRI, disease risk index; ELN, European Leukaemia Net; HCT-CI, Haematopoietic Cell Transplantation-Comorbidity Index; HLA, human leucocyte antigen; HR, hazard ratio; HSCT, haematopoietic stem cell transplantation; OS, overall survival; PB, peripheral blood; TBI, total body irradiation. *Unknown for 25 patients. †Unknown for two patients. ‡P-value for the whole subgroup analysis.
Bold marked values indicate observed significant difference, p<0.05.
Allogeneic HSCT in Relapsed or Refractory AML ª 2018 John Wiley & Sons Ltd based sequential conditioning regimens followed by an allogeneic HSCT. Long-term OS of more than one-third of these patients is encouraging, considering that conventional salvage regimens without subsequent allogeneic HSCT achieve longterm survival rates of less than 5% (Roboz et al, 2014; Thol et al, 2015; Dohner et al, 2017) . Thus, choice of the ideal conditioning therapy prior to HSCT appears to be a crucial step towards improving long-term survival of these patients, and future clinical trials may have to focus on further optimization of this regimen. In our study, older age, higher leukaemic burden, longer time interval between first diagnosis and HSCT, and transplantation from an HLA-mismatched unrelated donor were associated with inferior OS. These factors merit further attention to improve future transplantation strategies. First of all, time from diagnosis to transplantation should be as short as possible for patients with R/R-AML, as the application of several lines of therapy before HSCT may increase the risk of their disease being more resistant to the available therapies. Moreover, delaying transplantation will necessarily be accompanied by progressive disease in most of these patients, including increased thrombocytopenia and neutropenia with significant risks of bleeding and, even more importantly, of increased infectious complications beforehand, and will lower the chances for a successful outcome. In our study, more than 40% of the patients transplanted at an early time point after relapse or induction failure are alive and showed lower NRM rates when compared to those patients undergoing delayed allogeneic HSCT. Ultimately, progressive disease due to delayed application of allogeneic HSCT is associated with higher disease burden of the patients. We believe that reduction of disease burden immediately before starting doseadapted conditioning using our melphalan-based regimen was a key factor in allowing long-term disease control for a substantial number of patients. However, subgroup analyses of our study cohort still identified high disease burden prior to melphalan application as a relevant risk factor for poor outcome. Whereas the impact of disease status and cytogenetics was of less importance for long-term survival of our patients, higher blast counts prior to HSCT were associated with significantly shorter OS. As in most other available retrospective studies on patient cohorts, such as presented here, a general problem comes from unknown confounding factors and patient selection. Thus, results are more hypothesis-generating than hypothesis-confirming and have to be interpreted with due caution. For hypothesis confirmation, prospective and comparative trials are necessary. Consequently, future clinical trials should address the value of remission induction therapy versus direct early allogeneic HSCT in patients with R/R-AML. One randomized study addressing this question prospectively is the ongoing ETAL-3-ASAP trial (NCT02461537). Considering the high-risk situation of the patients analysed in our study, the cumulative incidences of NRM were comparable to those published for comparable patient cohorts (Shouval et al, 2015) . The increasing numbers of elderly AML patients undergoing allogeneic HSCT, will continue to require careful pre-transplant diagnostics and cautious planning of conditioning regimens for the reduction of NRM upon allogeneic HSCT. Further attempts to improve outcome by reducing the hazard for treatment-related death, particularly in elderly patients with R/R-AML, might be dose reductions of melphalan followed by less toxic, dose-reduced conditioning therapies within a sequential conditioning regimen.
Despite the importance of chemotherapeutic and prophylactic antimicrobial strategies, one of the main keys to achieve long-term disease-free survival remains immunological disease control via the graft-versus-leukaemia (GVL) effect. Interestingly, whereas HLA-identical sibling donors are largely considered as ideal donors for patients undergoing allogeneic HSCT, mainly due to an expected lower GvHD-related morbidity and lethality, in our study transplantation from a sibling donor was an independent risk factor for AML relapse. Thus, our data suggest that allografts from a HLA-matched unrelated donor produced a stronger GVL reaction and consequently better disease control compared to allografts from an HLA-identical sibling donor. Transplantation from an HLA-mismatched unrelated donor was equally associated with a significantly lower risk of leukaemia relapse. In contrast, transplantation from an HLA-mismatched unrelated donor showed a significantly higher NRM rate. Consequently, the higher NRM rate in this subgroup eventually outweighed the benefit of a lower incidence of leukaemia relapse. Future studies will have to validate prospectively whether the preference of a mismatched unrelated donor, even a haplo-identical donor, could be favourable for patients with active R/R-AML (Ballen, 2015; Ringden et al, 2017) .
Significant adverse risk factors for NRM in our study were older age, infection prior to conditioning therapy and a higher comorbidity index in a subset of patients, indicating the crucial relevance of optimized supportive care strategies. In these terms, our results confirm the prognostic role of active infections as well as prolonged neutropenia before starting conditioning therapy. As expected, patients requiring antimicrobial therapy beforehand showed inferior outcome. In our unselected cohort of patients with active R/R-AML, almost one third showed active infection, highlighting their high-risk situation. Given the dismal prognosis of patients with refractory AML and active infection and/or relevant comorbidities, allogeneic HSCT should not be a generally excluded procedure. In particular, effective supportive care regimens, including antimicrobial treatment and prophylaxis, prior to, as well as post transplantation are of importance. Our observed rates of early and late deaths are also in line with published data estimating NRM-rates and/or survival after allogeneic HSCT using defined prognosis scores (HCT-CI, EBMT-ADT, PAM) (Au et al, 2015; Shouval et al, 2015; Sorror et al, 2005) . Again, given the inferior prognosis of patients with R/R-AML with conventional treatment strategies, none of these prognostic scores are suitable for aiding the decision to exclude these patients from allogeneic HSCT.
In summary, allogeneic HSCT remains a powerful treatment option for patients with R/R-AML. Even though longterm survival of one third of our patients is far from being satisfactory, none of the alternative treatment strategies tested in the past few decades showed superior results for this verypoor prognosis group. Future prospective clinical trials in this high-risk patient group should be based on several approaches, such as further optimization of the conditioning regimens allowing optimal disease control without excessive toxicity, improved donor selection for augmenting GVL effects and incorporation of maintenance therapies using novel targeted therapies (Bug et al, 2015 (Bug et al, , 2017 Brunner et al, 2016a,b; Battipaglia et al, 2017; Stone et al, 2017) and/or prophylactic or pre-emptive donor lymphocyte infusions (Chang & Huang, 2013; Liga et al, 2013; Davids et al, 2016) . Given the substantial numbers of patients who die in remission months after transplantation, supportive care strategies will remain an essential backbone for successful HSCT in this setting.
